Stockscreener 앱 받기
115.46
2.38%
2.687
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo - BioPharma Dive
Gilead Announces Partnership With PEPFAR - Contract Pharma
Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries - BioSpace
Rx Rundown: Novartis, Gilead Sciences, Remedy Meds and more - Medical Marketing and Media
What to expect from Gilead Sciences Inc. in the next 30 daysMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
Gilead breaks ground on AI-enabled US manufacturing hub - European Pharmaceutical Review
Gilead Sciences’ Strategic Expansion in HIV Prevention and Global Access: Assessing Long-Term Investment Potential - AInvest
Gilead Sciences advances HIV prevention with new US partnership - Yahoo Finance
Momentum divergence signals in Gilead Sciences Inc. chartWeekly Trade Analysis & Risk Controlled Daily Trade Plans - Newser
Price action breakdown for Gilead Sciences Inc.2025 Volatility Report & Long-Term Growth Stock Strategies - Newser
Stock Analysis | Gilead Sciences OutlookA Strong Technical Picture with Mixed Analyst Signals - AInvest
What earnings revisions data tells us about Gilead Sciences Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - Newser
Gilead joins U.S. to expand access to new HIV drug (GILD) - Seeking Alpha
US plans to bring Gilead HIV drug to market in high-burden HIV countries - Reuters
Gilead partners with PEPFAR to expand HIV prevention access - Investing.com
U.S. to bring Gilead’s HIV drug lenacapavir to high-burden countries - Investing.com
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire
US Plans to Bring Gilead HIV Drug to Market in High-Burden HIV Countries - U.S. News & World Report
Gilead Sciences to Offer Lenacapavir at Cost for Global HIV Prevention - Devdiscourse
Gilead at Wells Fargo Conference: Strategic Growth and Challenges - Investing.com
Gilead Sciences breaks ground on new manufacturing hub - The Pharma Letter
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire
Real-World Experiences of People Living with HIV Prioritizing Their Well-Being - Gilead Sciences
'I can't wait to see where we go': Gilead launches $32 billion U.S. investment with new Foster City building - The Business Journals
Gilead Breaks Ground on Pharmaceutical Development & Manufacturing Technical Development Center - Contract Pharma
Gilead Sciences describes new Mpro inhibitors for SARS-CoV-2 - BioWorld MedTech
Gilead begins construction of new manufacturing centre in US - World Pharmaceutical Frontiers
Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Business Wire
Gilead, Amgen kick off facility investments in US - pharmaphorum
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Bakersfield.com
Is Gilead Sciences Stock Underperforming the Nasdaq? - Yahoo Finance
Gilead unveils new California manufacturing site, part of $32B US investment - FirstWord Pharma
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy - BioSpace
Is Gilead Sciences Stock Underperforming The Nasdaq? - Barchart.com
GILD Stock Quote Price and Forecast - CNN
Gilead breaks ground on AI-enabled biopharma hub at Foster City headquarters - KRON4
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Gilead Sciences’ Strategic Position in the Evolving Biopharma Landscape - AInvest
Gilead breaks ground on Foster City manufacturing hub as $32B US investment plan plays out - Fierce Pharma
Gilead at Cantor Global Healthcare Conference: Strategic Focus on Innovation - Investing.com
Gilead Sciences' $32 Billion U.S. Expansion and Its Implications for Biopharma Innovation and Stock Value - AInvest
Gilead Sciences $32B Investment in US Pharma ManufacturingNews and Statistics - IndexBox
Gilead Sciences’ $32 Billion U.S. Expansion and Its Implications for Biopharma Leadership - AInvest
4 Questions on Gilead’s New Technical Development Center with Stacey Ma & Jamie Moore - Gilead Sciences
Gilead Sciences Breaks Ground on New Manufacturing Center at California HQ - MarketScreener
Gilead's $32 Billion US Manufacturing Expansion: A Strategic Catalyst for Long-Term Shareholder Value - AInvest
Gilead breaks ground on manufacturing development site at California HQ - Seeking Alpha
Gilead breaks ground on new Bay Area facility as part of $32 billion investment By Investing.com - Investing.com
Gilead Sciences' $32 Billion U.S. Investment: A Strategic Catalyst for Biopharma Innovation and Shareholder Value - AInvest
Gilead Sciences breaks ground on new manufacturing facility in Foster City - StreetInsider
Intraday pattern recognizer results for Gilead Sciences Inc.Market Risk Analysis & Growth Focused Entry Reports - Newser
Will Gilead Sciences Inc. stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
How hedge fund analytics apply to Gilead Sciences Inc. stockTake Profit & Growth Oriented Trade Recommendations - Newser
Using RSI to spot recovery in Gilead Sciences Inc.2025 Retail Activity & High Return Stock Watch Alerts - Newser
Gilead's $0.5B Volume Ranks 215th as Q2 Sales Climb and Yeztugo Approval Signals Long-Term Innovation - AInvest
Market Trends: Can Gilead Sciences Inc. grow without external funding2025 Winners & Losers & Consistent Income Trade Ideas - khodrobank.com
Gilead is said to seek price hikes for HIV meds supplied for state AIDS drug programs - Seeking Alpha
What Do Analysts Think About Gilead Sciences (GILD)? - MSN
Gilead Sciences - Fierce Pharma
0.82%
2.11%
자본화:
|
볼륨(24시간):